

# Special Issue

## Feature Papers 2023

### Message from the Guest Editors

This is a collection of high-quality papers published free of charge in Open Access form by the editorial board members or invited by the editorial office and the Editor-in-Chief. The papers should be research papers (or review papers) with a full and detailed summary of the author's own research carried out to date.

---

### Guest Editors

Prof. Dr. Pierre Rougé

Institut de Recherche et Développement, Faculté de Pharmacie, UMR 152 PharmaDev, Université Paul Sabatier, 35 Chemin des Maraichers, 31062 Toulouse, France

Dr. Carmen Cuadrado

Instituto Nacional de Investigacion y Tecnologia Agraria y Alimentaria, Madrid, Spain

---

### Deadline for manuscript submissions

closed (31 December 2023)



## Allergies

---

an Open Access Journal  
by MDPI

---

Indexed in Scopus



[mdpi.com/si/154377](https://mdpi.com/si/154377)

*Allergies*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[allergies@mdpi.com](mailto:allergies@mdpi.com)

[mdpi.com/journal/  
allergies](https://mdpi.com/journal/allergies)





# Allergies

---

an Open Access Journal  
by MDPI

---

Indexed in Scopus



[mdpi.com/journal/  
allergies](https://mdpi.com/journal/allergies)



## About the Journal

### Message from the Editor-in-Chief

---

#### Editor-in-Chief

Prof. Dr. Pierre Rougé

Institut de Recherche et Développement, Faculté de Pharmacie, UMR  
152 PharmaDev, Université Paul Sabatier, 35 Chemin des Maraîchers,  
31062 Toulouse, France

---

#### Author Benefits

##### Open Access:

free for readers, with article processing charges (APC) paid  
by authors or their institutions.

##### High Visibility:

indexed within Scopus, Embase, and other databases.

##### Rapid Publication:

manuscripts are peer-reviewed and a first decision is  
provided to authors approximately 29.4 days after  
submission; acceptance to publication is undertaken in 6.2  
days (median values for papers published in this journal in  
the second half of 2025).